Stock Evaluator: Beyond Air, Inc. (XAIR)

Beyond Air, Inc. XAIR

$5.28 -0.15 -2.68%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 27,953
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Commentary & Analysis


Financial Summary

Share Statistics XAIR Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3.8 $337.2 3%
Shares Out (Mil) 0.7 41.9 3%
Institutional Ownership 80.7% 77.8% 50%
Float (Mil) 0.7 34.7 2%
Beta 0.22 0.85 13%
Avg Daily Volume (000s) 14 278 19%
Price Change
(52-week)
(91.2%) 58.7% 4%
Growth XAIR Industry
Median
Percentile
(All Stocks)
Sales (5yr) 53.6% 11.8% 96%
Net Income (5yr) (7.7%) (5.8%) 31%
EPS (5yr) 30.9% 11.4% 82
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (39.3%) (16.3%) 12%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS ($11.333) ($75.467) ($37.400)
Month Ago EPS na na na
# Rev Up 1 1 na
# Rev Down 1 0 na
Three Months Ago EPS ($9.000) ($81.000) na
Year/Year Chg (26.8%) (5.8%) (49.3%)
Financials XAIR Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $8 $152 8%
Net Income (TTM) (Mil) ($33) ($10) 20%
EPS (TTM) ($80.109) ($0.500) 1%
Operating Cash Flow (TTM) (Mil) ($18) ($2) 15%
Net Cash Flow (TTM) (Mil) $8 $1 55%
Long-Term Debt (Q1) (Mil) $23 $22 34%
Enterprise Value (Q1) (Mil) $16 $304 10%
Valuation XAIR Industry
Median
Percentile
(All Stocks)
P/B 0.51 2.80 9%
P/E na 31.1 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.9 na
Ratios XAIR Industry
Median
Percentile
(All Stocks)
Gross Margin 3.3% 59.1% 5%
Net Margin (433.0%) (7.3%) 2%
ROA (101.6%) (13.7%) 5%
ROE (337.4%) (15.8%) 2%
Liabilities to Assets 82.5% 44.7% 77%
F-Score 5 4 51%

Beyond Air, Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors